Biodesix (BDSX) PEG Ratio: History & Chart

Biodesix, Inc.(BDSX)

Medical - Diagnostics & Research · Louisville, CO

$29.55+0.49 (+1.69%)

Delayed quote: Oct 6, 2026, 9:34 AM EDT

About Biodesix, Inc.

Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinicians to evaluate the risk of lung cancer in patients with suspicious nodules, aiding in the reclassification of malignancy risk and guiding appropriate treatment pathways. Beyond risk assessment, Biodesix offers additional lung cancer diagnostics such as GeneStrat ddPCR, which detects specific tumor mutations, and VeriStrat, which gauges the patient's immune system status. Both are crucial for establishing prognosis and informing treatment plans. Another offering is the GeneStrat NGS (Next-Generation Sequencing) test, a rapid, blood-based sequencing solution providing results within 72 hours. Through a partnership with Bio-Rad Laboratories, Inc., Biodesix also provides COVID-19 testing services under its Biodesix WorkSafe program, featuring the Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test, an antibody assay for detecting a B-cell immune response indicating recent or prior infection. Furthermore, the company extends its expertise to biopharmaceutical companies, offering diagnostic and clinical research services, alongside clinical trial testing. It also actively discovers, develops, and commercializes companion diagnostics. Originally incorporated as Elston Technologies, Inc. in 2005, Biodesix, Inc. maintains its headquarters in Boulder, Colorado.

Louisville, CO

334 employees

www.biodesix.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Scott Hutton

View full financials

NAME	MARKET CAP	PEG RATIO	TTM	3Y	5Y
Biodesix, Inc. (BDSX)	$240.55M	N/A	N/A	N/A	N/A
High Tide Inc. (HITI)vs ›	$240.32M	N/A	N/A	N/A	N/A
Akebia Therapeutics, Inc. (AKBA)vs ›	$239.39M	N/A	N/A	N/A	N/A
BioAge Labs Inc. (BIOA)vs ›	$241.18M	N/A	N/A	N/A	N/A
Lifecore Biomedical, Inc. (LFCR)vs ›	$244.41M	N/A	2.31	2.31	2.31
Alector, Inc. (ALEC)vs ›	$232.03M	N/A	N/A	N/A	N/A
Galectin Therapeutics Inc. (GALT)vs ›	$240.38M	N/A	N/A	N/A	N/A
Keros Therapeutics, Inc. (KROS)vs ›	$230.09M	N/A	N/A	N/A	N/A
InflaRx N.V. (IFRX)vs ›	$247.60M	N/A	N/A	N/A	N/A
Greenwich LifeSciences, Inc. (GLSI)vs ›	$249.24M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PEG RATIO

TTM

Biodesix, Inc. (BDSX)

$240.55M

N/A

High Tide Inc. (HITI)vs ›

$240.32M

N/A

Akebia Therapeutics, Inc. (AKBA)vs ›

$239.39M

N/A

BioAge Labs Inc. (BIOA)vs ›

$241.18M

N/A

Lifecore Biomedical, Inc. (LFCR)vs ›

$244.41M

N/A

2.31

Alector, Inc. (ALEC)vs ›

$232.03M

N/A

Galectin Therapeutics Inc. (GALT)vs ›

$240.38M

N/A

Keros Therapeutics, Inc. (KROS)vs ›

$230.09M

N/A

InflaRx N.V. (IFRX)vs ›

$247.60M

N/A

Greenwich LifeSciences, Inc. (GLSI)vs ›

$249.24M

N/A

PEG Ratio Formula & Definition

PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)

The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.

PEG Ratio: N/A

BDSX PEG Ratio Metrics

BDSX Competitors' PEG Ratio

Growth-Adjusted Valuation

PEG Ratio Formula & Definition

Related Metrics